Member
No results available
Spain’s foreign investment screening regime has become one of the most consequential regulatory hurdles for cross‑border M&A in Western Europe, and the landscape entering 2026 demands careful planning from every foreign buyer. The extension of transitional screening obligations to EU and EFTA investors through Decree‑Law 1/2025, published on 29 January 2025, means that even intra‑European acquirers now face prior‑authorisation requirements when targeting strategic Spanish sectors. At the same time, the European Parliament’s ongoing revision of the EU FDI Screening Regulation is set to tighten coordination between national authorities and Brussels.
This guide provides an actionable, step‑by‑step framework for foreign counsel, in‑house legal teams and private‑equity sponsors to navigate foreign investment screening Spain 2026 obligations, from initial sector analysis through notification, SPA drafting and conditional closing.
The Spanish FDI screening regime applies to any transaction that gives a foreign investor effective control, or, in certain strategic sectors, a significant stake, in a Spanish company operating in defence, critical infrastructure, ICT, AI and semiconductors, healthcare and life sciences, energy, or transport. Since Decree‑Law 1/2025, the screening net has widened: EU and EFTA investors that were previously exempt must now also obtain prior authorisation for specified sectors until at least the end of 2026.
Review timelines vary, but deal teams should budget several weeks for the completeness assessment phase and additional months for substantive review, with the possibility of extensions where remedies are under negotiation. Early engagement with the Spanish Ministry of Commerce (Subdirección General de Inversiones Exteriores) is the single most effective lever for shortening the overall timeline.
The practical effect for buyers is threefold: every deal in a sensitive sector needs an FDI screening risk assessment before the letter of intent is signed; notification planning and regulatory closing conditions must be baked into the SPA from day one; and due diligence must be calibrated to surface national‑security red flags that could trigger a block or conditional clearance.
Three‑point buyer action checklist:
Spain’s FDI screening architecture rests on several layers of national and European law. Understanding how these layers interact, and how they have shifted since 2024, is essential for any buyer structuring cross‑border M&A Spain transactions.
The primary national statute governing foreign investment control is Law 19/2003 on the legal regime for capital movements and economic transactions abroad, supplemented by Royal Decree 664/1999 and its subsequent amendments. The screening mechanism for national‑security purposes was substantially introduced by Royal Decree‑Law 8/2020 (adopted during the COVID‑19 emergency) and has since been extended repeatedly. The most recent extension, Decree‑Law 1/2025, was published in the Boletín Oficial del Estado (BOE) on 29 January 2025 and formally extends the transitional FDI screening regime for EU and EFTA investors through to the end of 2026. The Spanish Ministry of Industry and Commerce’s Control of Investments page provides official procedural guidance and downloadable forms.
At the European level, the EU FDI Screening Regulation (Regulation 2019/452) creates a cooperation mechanism between Member States and the European Commission. The European Parliament confirmed on 24 February 2026 that a legislative revision of this regulation is progressing, with the aim of strengthening mandatory screening obligations and expanding the list of sectors subject to coordination.
| Date | Instrument / Event | Significance for buyers |
|---|---|---|
| March 2020 | Royal Decree‑Law 8/2020 | Introduced mandatory FDI screening for non‑EU investors in strategic sectors |
| 29 January 2025 | Decree‑Law 1/2025 (BOE) | Extended transitional screening regime to EU/EFTA investors through end‑2026 |
| October 2025 | EU FDI Fifth Annual Report | Highlighted increasing volume and complexity of screening cases across Member States |
| January 2026 | Updated Ministry of Commerce guidance | Clarified notification procedures, sector definitions and document requirements |
| 24 February 2026 | European Parliament, EU FDI Regulation revision update | Signals forthcoming mandatory EU‑wide screening; may expand sectors and lower thresholds |
Industry observers expect the interplay between Spain’s national rules and the forthcoming EU revision to create a period of heightened uncertainty in H2 2026. Deal teams should monitor both tracks in parallel.
Not every acquisition involving a foreign buyer triggers Spain’s screening mechanism. The obligation depends on three variables: who the investor is (origin and entity type), what the target does (sector), and how much control the transaction confers. The following comparison table summarises Spain regulatory approvals M&A obligations by entity type.
| Entity Type | When Reporting / Notification Required | Key Differences / Notes |
|---|---|---|
| Non‑EU / third‑country investor (acquisition of control) | Prior authorisation required when a sector trigger is present or control thresholds are met | Full dossier; higher scrutiny; potential for remedies or block |
| EU / EFTA investor (transitional regime through 2026; Decree‑Law 1/2025) | Transitional reporting and possible prior authorisation for specified strategic sectors until end‑2026 | Lower friction than third‑country in some instances, but still subject to screening for strategic sectors |
| Minority investment (<10% share) | Often exempt, but depends on shareholder rights and effective‑control tests | Check governance rights, veto powers and protective provisions that could amount to de facto control |
Spain’s screening regime covers a broad and growing list of sectors. The following are the principal categories that trigger enhanced review, particularly where a Spain national security review M&A assessment is warranted:
Control thresholds are not limited to majority stakes. Acquisitions of 10% or more can trigger screening where the investor gains board representation, veto rights over strategic decisions, or access to sensitive technology or data. The Ministry’s guidance emphasises a substance‑over‑form approach: the test is effective control, not merely the percentage of shares acquired.
Certain transactions fall outside the screening net. Portfolio investments with no governance rights (pure financial stakes below 10% without protective provisions) are typically exempt. The Ministry’s guidance also notes that investments below specified turnover thresholds may qualify for simplified treatment, although these exemptions vary by sector and investor origin. Buyers should confirm the applicable de minimis rules against the most current ministerial guidance, as thresholds have been adjusted in previous extensions and the likely practical effect of the EU revision will be to narrow exemptions further.
Understanding the administrative pathway is critical for deal sequencing. Spain’s foreign investment screening process is administered by the Subdirección General de Inversiones Exteriores, which sits within the Ministry of Industry, Commerce and Tourism. The Council of Ministers retains ultimate authority to approve, conditionally clear or block a notified transaction.
The Ministry’s Control of Investments page provides the official application form and procedural instructions. A complete dossier typically includes:
While Spain does not operate a formal fast‑track procedure equivalent to some other European jurisdictions, voluntary pre‑notification consultation with the Ministry can function as an informal accelerator. Buyers who present a complete, well‑structured dossier and proactively address likely concerns, for example, by offering governance commitments or data‑localisation undertakings, tend to receive faster resolutions.
Timeline uncertainty is one of the biggest deal‑management challenges in cross‑border M&A Spain. The following table sets out indicative durations for each phase of the screening process, based on practitioner experience and publicly available guidance.
| Phase | Standard Duration | Extended / Complex Cases |
|---|---|---|
| Pre‑notification dialogue (voluntary) | 2–4 weeks | Up to 6 weeks for novel sectors |
| Completeness check (after formal filing) | Up to 30 days | Clock stops for RFIs |
| Substantive review | 30–45 days | Up to 90 days with extensions |
| Remedy negotiation (if applicable) | Additional 30–60 days | Can extend total to 150+ days |
| Council of Ministers decision | Scheduled at next available session | Variable |
Key takeaway: From formal filing to unconditional clearance, buyers should plan for a minimum of 8–12 weeks. Complex or sensitive cases, particularly in defence, AI or healthcare, can extend well beyond that range.
The Ministry is most likely to move toward conditional clearance (rather than a straight block) when the transaction presents identifiable but manageable risks. Typical triggers for remedy discussions include the target’s access to classified information, critical supply‑chain dependencies, or cross‑border data flows that could expose sensitive personal or governmental data.
Standard financial and legal due diligence is necessary but insufficient for a transaction that may trigger foreign investment screening. Buyers must layer a regulatory‑risk lens over the conventional diligence workstreams. The following foreign buyer checklist Spain covers the most critical areas.
Tech M&A Spain 2026: Targets with AI training datasets sourced from or linked to government agencies; cloud‑infrastructure contracts with public‑sector clients; semiconductor IP that could be classified as dual‑use; and cybersecurity products deployed in critical‑infrastructure settings.
Life sciences M&A Spain: Pharmaceutical manufacturers with products on Spain’s essential‑medicines list; biotech firms conducting research funded by the Spanish government or the EU Horizon programme; medical‑device companies supplying the national health system (SNS); and entities holding clinical‑trial data that includes sensitive personal health information.
The SPA is the buyer’s primary contractual instrument for managing FDI screening risk. Poorly drafted regulatory provisions can leave a buyer trapped between an unconditional obligation to close and an outstanding government prohibition. The following drafting strategies reflect current best practice in cross‑border M&A Spain.
Conditionality. Include a specific regulatory‑approval condition precedent referencing the Spanish FDI screening clearance. Define “clearance” precisely, unconditional approval, approval subject to acceptable conditions, or deemed approval through the lapse of the statutory review period without a decision.
Longstop dates. Set the longstop date (outside date) with realistic reference to the timelines in the table above. A minimum of six months from signing is prudent for strategic sectors; nine to twelve months is advisable where remedy negotiation is likely.
Reverse break fees. Where the seller demands deal certainty, offer a reverse break fee payable by the buyer if clearance is not obtained within the longstop period. Calibrate the fee to the realistic risk of a block (which remains statistically rare in Spain) rather than to a worst‑case scenario.
Cooperation covenants. Obligate both parties to cooperate in the notification process: the seller provides access to information and personnel for dossier preparation; the buyer commits to filing promptly and responding to RFIs within specified timeframes.
Interim operating covenants. Restrict the seller from taking actions during the review period that could prejudice the screening outcome, for example, terminating government contracts, transferring IP, or altering data‑processing arrangements.
The following short‑form clause examples illustrate the key drafting points. They should be adapted to the specific transaction and reviewed by Spanish counsel.
Outright blocks remain the exception in Spain; conditional approvals with tailored remedies are far more common. Understanding the range of remedies and the enforcement framework helps buyers negotiate proportionate outcomes and structure deals accordingly.
Common remedy types imposed in practice include:
Closing a screened transaction without obtaining the required prior authorisation exposes the buyer to administrative fines and potential forced unwinding of the acquisition. The Ministry has the power to declare a non‑notified transaction void and to impose financial penalties. Timely voluntary notification and proactive remediation proposals significantly reduce enforcement risk.
In one reported instance, a non‑EU technology investor acquiring a Spanish cybersecurity firm was required to establish a separate Spanish subsidiary to hold the target’s government contracts, with an independent board that included a Ministry‑approved director. In another case, a life‑sciences acquirer was required to maintain domestic manufacturing capacity for essential medical devices and to store all clinical‑trial data on EU‑based servers. Both transactions were ultimately cleared with conditions.
The following anonymised vignettes illustrate how foreign investment screening played out in two high‑profile sectors and the practical tools buyers deployed to manage risk.
A US‑based private‑equity fund sought to acquire a Barcelona‑headquartered AI software company that provided predictive‑analytics solutions to several Spanish public‑sector clients, including regional health authorities. The target’s platform processed significant volumes of sensitive personal data. The buyer’s deal team identified the FDI screening trigger during due diligence and elected to engage the Ministry through a voluntary pre‑notification consultation. During the substantive review phase, the Ministry raised concerns about cross‑border data flows and the acquirer’s ultimate ownership structure, which included a minority LP based in a non‑allied jurisdiction.
The buyer proposed a package of remedies: data localisation within Spain, the appointment of an independent data‑protection officer approved by the Ministry, and a commitment to maintain the Spanish engineering team for a minimum of three years. Clearance with conditions was granted within approximately four months of formal filing. The SPA’s longstop date, set at nine months, provided adequate headroom.
A Japanese pharmaceutical group pursued the acquisition of a Madrid‑based MedTech company that manufactured diagnostic equipment supplied to Spain’s national health system (SNS). The target held several EU medical‑device certifications and was a participant in an EU Horizon‑funded research consortium. The buyer filed a complete dossier shortly after signing the SPA, which included a regulatory‑approval condition precedent and cooperation covenants. The Ministry’s review focused on continuity of supply to the SNS and the integrity of ongoing EU‑funded research. The negotiated remedies included a five‑year commitment to maintain domestic manufacturing capacity, continued participation in the Horizon consortium through its scheduled conclusion, and restrictions on the transfer of key patents outside the EU.
The total timeline from filing to clearance was approximately three and a half months, faster than average, attributed by industry observers to the buyer’s comprehensive dossier and proactive remedy offer.
The following resources are designed to support deal teams from initial screening assessment through to closing:
Foreign investment screening Spain 2026 is not a static compliance exercise, the regulatory framework is actively evolving at both the national and EU levels. Buyers who integrate screening analysis into their earliest deal planning, prepare thorough notification dossiers and draft SPAs with realistic regulatory timelines will be best positioned to close transactions efficiently and on favourable terms. For a tailored screening assessment based on a specific transaction, Global Law Experts can connect you with experienced Spanish M&A counsel.
This article was produced by Global Law Experts. For specialist advice on this topic, contact Jordi Casas at Osborne Clarke, a member of the Global Law Experts network.
posted 5 minutes ago
posted 29 minutes ago
posted 55 minutes ago
posted 1 hour ago
posted 2 hours ago
posted 2 hours ago
posted 3 hours ago
posted 3 hours ago
posted 4 hours ago
posted 4 hours ago
posted 5 hours ago
posted 5 hours ago
No results available
Find the right Legal Expert for your business
Sign up for the latest legal briefings and news within Global Law Experts’ community, as well as a whole host of features, editorial and conference updates direct to your email inbox.
Naturally you can unsubscribe at any time.
Global Law Experts is dedicated to providing exceptional legal services to clients around the world. With a vast network of highly skilled and experienced lawyers, we are committed to delivering innovative and tailored solutions to meet the diverse needs of our clients in various jurisdictions.
Global Law Experts is dedicated to providing exceptional legal services to clients around the world. With a vast network of highly skilled and experienced lawyers, we are committed to delivering innovative and tailored solutions to meet the diverse needs of our clients in various jurisdictions.
Send welcome message